Anti-PIP4K2B antibodies have been detected in 50% (seven out of fourteen) of the SSc patients negative to the autoantibody panel routinely measured at our clinic, including anti-TOPO-1/Scl70 and anti-centromere (Figure 3a). Here, PIP4K2B is linked to systemic sclerosis.